Literature DB >> 26969091

Adjuvant therapy for renal-cell carcinoma: settled for now.

Stefan Duensing1, Markus Hohenfellner2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26969091     DOI: 10.1016/S0140-6736(16)00653-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  [Level IV inferior vena cava tumor thrombus : A rare diagnosis in patients with renal cell carcinoma].

Authors:  L Hofer; C Gasch; G Hatiboglu; J Motsch; C Grüllich; S Duensing; M Hohenfellner
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

2.  Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

3.  Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.

Authors:  U Batra; P M Parikh; K Prabhash; H B Tongaonkar; P Chibber; D Dabkara; C Deshmukh; N Ghadyalpatil; S Hingmire; A Joshi; S K Raghunath; S Rajappa; R Rajendranath; S K Rawal; Manisha Singh; R Singh; S P Somashekhar; R Sood
Journal:  South Asian J Cancer       Date:  2016 Oct-Dec

4.  Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma.

Authors:  Junyao Duan; Xu Bao; Xin Ma; Yu Zhang; Dong Ni; Hanfeng Wang; Fan Zhang; Qingshan Du; Yang Fan; Jianwen Chen; Shengpan Wu; Xintao Li; Yu Gao; Xu Zhang
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

5.  Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway.

Authors:  Yun-Sok Ha; Yeon-Yong Kim; Na Hee Yu; So Young Chun; Seock Hwan Choi; Jun Nyung Lee; Bum Soo Kim; Eun Sang Yoo; Tae Gyun Kwon
Journal:  Investig Clin Urol       Date:  2018-05-18

6.  Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma.

Authors:  Bin Wang; Lixiao Liu; Jinting Wu; Xiaolu Mao; Zhen Fang; Yingyu Chen; Wenfeng Li
Journal:  Front Genet       Date:  2022-02-09       Impact factor: 4.599

Review 7.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

8.  Tetrandrine inhibits migration and invasion of human renal cell carcinoma by regulating Akt/NF-κB/MMP-9 signaling.

Authors:  Shurui Chen; Wei Liu; Ke Wang; Yizeng Fan; Jiaqi Chen; Jianbin Ma; Xinyang Wang; Dalin He; Jin Zeng; Lei Li
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

9.  Rhein inhibits malignant phenotypes of human renal cell carcinoma by impacting on MAPK/NF-κB signaling pathways.

Authors:  Ya-Li Ma; Fang Chen; Jun Shi
Journal:  Onco Targets Ther       Date:  2018-03-14       Impact factor: 4.147

10.  A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.

Authors:  Sha Wu; Xiaoning Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.